Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
[출처/시간] Briefing.com - 5:26 PM ET, 05/21/2026 TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-nave patients with advanced ALK-positive NSCLCClick here for full release.
[출처/시간] Briefing.com - 5:26 PM ET, 05/21/2026
TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-nave patients with advanced ALK-positive NSCLCClick here for full release.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
